INFLUENCE OF PHYTOCOMPOSITIONS ON DYNAMICS OF CHANGES IN BASAL GLYCEMIA AND GLYCEMIA IN ORAL GLUCOSE TOLERANCE TEST IN RATS WITH STREPTOZOTOCIN-NICOTINAMIDE-INDUCED DIABETES MELLITUS TYPE 2.

Diabetes mellitus is one of the global medical, social and economic problems of today.Therefore, it is important to develop a new mechanism of action with fewer side effects that can reduce glycemia and insulin resistance. The aim of the study was to determine the effect of phytocompositions on the basis of Galega officinalis L. and Galevit in the conditions of therapeutic and prophylactic use in experimental type 2 diabetes mellitus contribute to the recovery of carbohydrate metabolism.on the dynamics of changes in basal glycemia and glycemia after oral glucose tolerance test in animals under conditions of experimental streptozotocin diabetes. The composition of the maturing phytocomposition and its lipocomposite form includes dry extract Galega officinalis L. - 50.0 mg, dry extract of Vaccinium myrtillus L. leaf - 50.0 mg, taurine - 1.4 mg. Type 2 diabetes mellitus was modeled on the method of Islam S., Choi H. 50 nonlinear white rats-males body weighing 180-220 g were used for the experimental studies.All animals were randomized into 5 groups of 10 rats: 1 - control group; 2 - animals with with T2DM; 3 - animals with diabetes mellitus, which received reference drugs (Arfa combi); 4 - STZ+N and substances received phytocomposition; 5 - STZ+N and Galevit. The investigated phytocompositions were administered intragastrically once a day for 28 days, starting 24 h after induction of type 2 diabetes mellitus. Phytocompositionson the basis of Galega officinalis L. and Galevit in the conditions of therapeutic and prophylactic use in experimental type 2 diabetes mellitus contribute to the recovery of carbohydrate metabolism. At the effectiveness of correction of metabolic changes, in experimental diabetes mellitus, phytocomposition based on Galega officinalis L. is not inferior, and liposomal form of dry extract Galevit is dominated by the reference phyto-agent Arfa combi. The spectrum of metabolic activity and the effectiveness of the therapeutic and prophylactic action of the application of the liposomal form of this phytocomposition under the conditional name Galevit is more justified on the basis of pathological changes, and the develo-pment of a new antidiabetic herbal remedy is more expedient.

[MIELIN BASIC PROTEIN IN THE BRAIN TISSUE OF THE BALB/C MICE WITH EXPERIMENTAL ANTIPHOSPHOLIPID SYNDROME AND AFFECTION WITH NITRIC OXIDE SYNTHESIS MODULATORS].

The aim of the research was to study the content of myelin basic protein (MBP) in the cerebellum and cerebral hemispheres of the BALB/c mice with experimental antiphospholipid syndrome as well as in cases of introduction of L-arginine and aminoguanidine. The research was performed using 50 female BALB/c mice, in which APS was simulated. L-arginine (25 mg/kg) and aminoguanidine (10 mg/kg) were used for correction. A Western blot analysis of the main myelin protein (antibodies against MBP) as well as a densitometric analysis of immunoreactive zones was carried out using the samples of the cerebellum and cerebral hemispheres of the control and experimental BALB/c mice. The increased content of MBP (18.4 kDa) in 256 times (p<0.001) in the tissue of the cerebral hemispheres of the BALB/c mice with antiphospholipid syndrome was evidenced compare to the control. It was found out that in the samples of the cerebral hemispheres, the content of MBP (18.4 kDa) increased in 4.8 times (p<0.001) with the use of L-arginine, in 10 times (p<0.001) - with aminoguanidine, in 13 times (p<0.001) - in cases of the combined use of L-arginine and aminoguanidine compare to the indices of the mice with antiphospholipid syndrome. It was proved that the content of MBP (95-110 kDa) in the samples of the cerebral hemispheres of the experimental animals did not significantly change compare to the control. In the cerebellum of the animals with antiphospholipid syndrome, it was established that the level of MBP (95-110 kDa) increased in more than 5 times (p<0.001), while the MBP (18.4 kDa) was found in very small amounts compare to the control. In cases of lone and combined use of nitric oxide synthesis modulators (L-arginine and aminoguanidine), there were no significant changes in the level of MBP (95-110 kDa) in the cerebellum of BALB/c mice with antiphospholipid syndrome compare to the indices of the BALB/c mice with antiphospholipid syndrome only.